RJA
PHAS

Raymond James & Associates’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Raymond James & Associates’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,500
Closed -$3K – 4133
2022
Q3 		$3K Hold
15,500
– – ﹤0.01% 3913
2022
Q2 		$9K Hold
15,500
– – ﹤0.01% 3947
2022
Q1 		$20K Hold
15,500
– – ﹤0.01% 4009
2021
Q4 		$40K Buy
+15,500
New +$46.8K ﹤0.01% 3976

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Raymond James & Associates's PHAS Position: Q4 2022 in Review

Raymond James & Associates sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 15,500 shares — an estimated $3K sold.

Raymond James & Associates first reported a position in PHAS in Q4 2021 and held it in 4 quarters. The position peaked at $40K in Q4 2021. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • Raymond James & Associates reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 15,500 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $3K.
  • Raymond James & Associates first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • Raymond James & Associates's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $40K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.